Protocolo terapéutico de los trastornos del humor

  1. Alberdi Páramo, Íñigo 1
  2. Pérez Lombardo, M. 1
  3. Álvarez Mon, M.Á. 2
  4. Molina Ruiz, R. 1
  1. 1 Instituto de Psiquiatría y Salud Mental, Hospital Clínico San Carlos, Madrid, España
  2. 2 Departamento de Psiquiatría Hospital Infanta Leonor, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2023

Título del ejemplar: Enfermedades psiquiátricas (I): Trastornos de ansiedad, afectivos y adaptativos

Serie: 13

Número: 84

Páginas: 4970-4977

Tipo: Artículo

DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

El tratamiento de los trastornos del humor incluye el uso de antidepresivos y de estabilizadores del humor en el trastorno bipolar y, en algunos casos, de depresión resistente. El tratamiento debe ser acorde con la gravedad, personalizado para cada caso, integrador y basado en la evidencia científica. Las medidas terapéuticas incluyen también pautas higiénico-dietéticas, ejercicio físico, psicoterapia, rehabilitación funcional y, en ocasiones, terapia electroconvulsiva. Este protocolo incluye algoritmos, tablas y figuras con el objetivo de facilitar la decisión del tratamiento farmacológico a emplear.

Referencias bibliográficas

  • Pereira Sánchez V, Molero Santos P. Protocolo diagnóstico y terapéutico de la depresión. Medicine. 2019;12(86):5070-4.
  • Trivedi MH, ed. Manual de depresión. Madrid: Grupo Aula Médica; 2021.
  • Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065.
  • McIntyre RS, Berk M, Brietzke E, Goldstein BI, López Jaramillo C, Kessing LV. Bipolar disorders. Lancet. 2020;396(10265):1841- 56.
  • Arrieta M, Molero Santos P. Protocolo diagnóstico y terapéutico del paciente con trastorno bipolar. Medicine (Baltimore). 2019;12(86):5081-7.
  • Taylor DM, Barnes TR, Young AH. The Maudsley. Prescribing guidelines in Psychiatry. 14a ed. Wiley-Blackwell; 2021.
  • Gartlehner G, Thaler K, Hill S, Hansen RA. How should primary care doctors select which antidepressants to administer? Curr Psychiatry Rep, 2012;14(4):360-9.
  • Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299-312.
  • Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 2018;391(10128):1357-66.
  • Stahl SM. Guía del prescriptor. Antidepresivos. 2017.
  • Sadock B, Sadock V, Ruiz P. Sinopsis de Psiquiatría. Kaplan HI, Sadock BJ, eds. Ciencias del comportamiento/Psiquiatría clínica. Wolters Kluwer; 2015.
  • Stahl SM. Stahl´s essential psychopharmacology. Prescriber´s Guide. 6ª ed. Cambridge; 2017.
  • Álamo C, López Muñoz F. Fármacos antidepresivos. En: Terapéutica farmacológica de los trastornos del sistema nervioso Programa de Actualización en Farmacología y Farmacoterapia. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos; 2012. p. 345-82.
  • Alberdi Páramo Í, Barbudo del Cura E. Psicofármacos 2. En: Manual de Psiquiatría. 2a ed. Amir Salud, S.L.; 2021.
  • Thase M, Connolly R. Unipolar depression in adults: Choosing treatment for resistant depression. UpToDate 2020.
  • Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43-64.
  • Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological Treatments. Can J Psychiatry, 2016;61(9):540-60.
  • Pérez Sola V, Puigdemont D, Mora L, Álvarez P, De Diego FJ. Depresión mayor unipolar y resistencia al tratamiento. In: Depresiones Bipolares y Unipolares Qué hacer en los pacientes que no responden suficientemente a los tratamientos habituales. Madrid: Editorial Médica Panamericana; 2019. p. 13-32.
  • Vieta E, Colom F. Therapeutic options in treatment-resistant depression. Ann Med, 2011;43(7):512–30.
  • Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry. 2019;214(1):42-51.
  • Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol, 2015;29(5):459-525.
  • Spijker J, Nolen W. An algorithm for the pharmacological treatment of depression. Acta Psychiatr Scand, 2010;121:180.
  • Cardoner Álvarez N. Abordaje farmacológico y terapias físicas. En: Pautas de actuación y seguimiento. Depresión. 2023. p. 53-74.
  • Kini V, Ho PM. Interventions to improve medication adherence: A review. JAMA. 2018;320(23):2461-73.
  • Wisniewski SR, Fava M, Trivedi MH, Thase ME, Warden D, Niederehe G. Acceptability of second-step treatments to depressed outpatients: A STAR*D report. Am J Psychiatry. 2007;164(5):753-60.
  • Hirschfeld RMA, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M. Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options. J Clin Psychiatry. 2002;63(9):826-37.
  • Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67(12):1836-55.
  • Reichenpfader U, Gartlehner G, Morgan L. Sexual dysfunction associated with second generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis. Drug Saf. 2014;37:19.
  • Rush AJ. Unipolar major depression in adults: Choosing initial treatment. UpToDate. 2020.
  • Schatzberg A, Nemeroff C. The American Psychiatric Association Publishing Textbook of Psychopharmacology. 2017.
  • Wenzel Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int. 2011;108:687.
  • McLachlan G. Treatment resistant depression: what are the options? BMJ, 2018;363:k5354.
  • Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment. JAMA, 2017;318(2):132-45.
  • Davies P, Ijaz S, Williams CJ, Kessler D, Lewis G, Wiles N. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2019;12(12):CD010557.
  • Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN. STAR*D. CNS Drugs. 2009;23(8):627-47.
  • Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult chinese patients with treatment-resistant major depression. J Clin Psychopharmacol, 2011;31(5):638-42.
  • Bauer M, Dell’Osso L, Kasper S, Pitchot W, Vansvik ED, Köhler J. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord, 2013;151(1):209-19.
  • Bradley AJ, Lenox Smith AJ. Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. J Psychopharmacol, 2013;27(8):740-58.
  • Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry. 2018;75(2):139-48.
  • Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry, 2018;175(7):620-30.
  • Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry, 2017;74(4):399-405.
  • Yatham LN, Kennedy SH, Parikh S V, Schaffer A, Bond DJ, Frey BN. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord, 2018;20(2):97-170.
  • Pacchiarotti I, Anmella G, Colomer L, Vieta E. How to treat mania. Acta Psychiatr Scand, 2020;142(3):173-92.
  • Hunt J. Manic-depressive illness: Bipolar disorders and recurrent depression. J Am Acad Child Adolesc Psychiatry, 2008;47(10):1208-9.
  • Bermejo Pastor A, Alberdi Páramo Í. Trastorno bipolar, ciclotimia, suicidio y trastornos puerperales. En: Manual de psiquiatría. 2a ed. Madrid: Amir Salud, S.L.; 2021.
Fuente de los datos: Dialnet